A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.

MLA

Cuba, Lisa, et al. “A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.” JCO Oncology Practice, vol. 20, no. 9, Sept. 2024, pp. 1219–30. EBSCOhost, https://doi.org/10.1200/OP.23.00694.

APA

Cuba, L., Dürr, P., Gessner, K., Häcker, B., Fietkau, R., Siebler, J., Pavel, M., Neurath, M. F., Berking, C., Wullich, B., Brückl, V., Beckmann, M. W., Fromm, M. F., & Dörje, F. (2024). A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center. JCO Oncology Practice, 20(9), 1219–1230. https://doi.org/10.1200/OP.23.00694

Chicago

Cuba, Lisa, Pauline Dürr, Katja Gessner, Babette Häcker, Rainer Fietkau, Jürgen Siebler, Marianne Pavel, et al. 2024. “A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.” JCO Oncology Practice 20 (9): 1219–30. doi:10.1200/OP.23.00694.